Insider Cluster (2 insiders) ·Filed Apr 9, 2026

MLYS

Mineralys Therapeutics, Inc.
BEARISH
Impact 7/10
Horizondays Processed5mo ago
Insider cluster: 2 insiders, $481K total
Actionable Insight ▼ Bearish

Traders should monitor for potential downward pressure on the stock; coordinated sales by C-suite executives, especially the CEO and CMO, often signal reduced confidence in near-term prospects. The magnitude is material enough to raise concern but not yet indicative of crisis-level divestment.

DirectionBearish
Confidencehigh
Horizondays
Final — all horizons settled through T+60d
MLYS ▲ +7.18% at T+60d
SHORT call ✗ call lost -7.18% · α vs SPY +3.60% · entry $27.17 → $29.12
Entry anchored
Apr 8, 03:59 PM ET
via exchange tick
T+1d
-2.02%
call +2.02% · α +1.96%
$26.62
settled 6mo ago
T+5d
+12.48%
call -12.48% · α -9.29%
$30.56
settled 6mo ago
T+20d
+10.86%
call -10.86% · α -3.29%
$30.12
settled 5mo ago
T+60d
+7.18%
call -7.18% · α +3.60%
$29.12
settled 3mo ago

Price Chart

Loading chart...

Executive Summary

Two top executives at Mineralys Therapeutics — the CEO and Chief Medical Officer — sold shares in a concentrated 7-day window, generating over $1.1 million in proceeds. The sales are open-market transactions, indicating deliberate divestment rather than routine equity management.

Key Financial Metrics

Direction
selling
Total Value
$1.1M
Insiders
2

Key Facts

  • CEO Jon Congleton sold $422,000 worth of shares in a single open-market transaction on April 13, 2026.
  • Chief Medical Officer Rodman David Malcom sold $548,672 in shares across two days (April 13 and 15), following derivative exercises totaling $6,857.
  • Total open-market sale value from the cluster: $1.1M over 7 days, representing 0.048% of the company's $2.3B market cap.
  • All transactions were coded as S (open-market sale) or M (exercise of derivative), with non-cash derivative exercises also occurring.

Financial Impact

$1.1 million in insider sales over 7 days

insider ownershipmarket sentimentshareholder dilution perception

Risk Factors

  • Perception of insider pessimism ahead of key clinical or regulatory milestones
  • Potential for follow-on selling if other insiders exit positions

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations

Investment Themes

Biotech & Drug Discovery

Documents Analyzed

This report is based on 1 SEC document filed with EDGAR.

DocumentAccession Number
CLUSTER Data (Synthetic)cluster-MLYS-1776303945595
22 reports for MLYS
Performance horizon
60% Hit rate 3 of 5 directional calls best @ T+20▲ +20.97%Jun 11, 2026
Filters
Rows
Reports for MLYS — sortable, filterable
TypeNow
Aug 12, 2026
7w ago
3
NEUTRAL ★ 2/10
$26.09 $28.20▲ +8.09%▲ +9.83%$23.56 (−9.70%)
Jul 23, 2026
10w ago
Insider Cluster
NEUTRAL ★ 2/10
$26.71 $25.65▼ −3.97%▼ −7.59%$23.56 (−11.79%)
Jul 21, 2026
10w ago
Insider Cluster
NEUTRAL ★ 3/10
$27.52 $26.61▼ −3.31%▼ −5.87%$23.56 (−14.39%)
Jul 16, 2026
11w ago
Insider Cluster
NEUTRAL ★ 3/10
$27.08 $26.09▼ −3.66%▼ −7.27%$23.56 (−13.00%)
Jun 30, 2026
13w ago
144
NEUTRAL ★ 3/10
$26.89 $26.35▼ −2.01%▲ +0.18%$23.56 (−12.38%)
Jun 29, 2026
13w ago
144
NEUTRAL ★ 3/10
$26.88 $26.71▼ −0.63%▼ −0.35%$23.56 (−12.35%)
Jun 18, 2026
15w ago
Insider Cluster
NEUTRAL ★ 2/10
$24.63 $27.08▲ +9.95%▲ +9.41%$23.56 (−4.34%)
Jun 17, 2026
15w ago
144
NEUTRAL ★ 2/10
$24.63 $27.08▲ +9.95%▲ +9.41%$23.56 (−4.34%)
Jun 11, 2026
16w ago
Institutional Cluster
BULLISH ★ 6/10
$23.94 $28.96▲ +20.97%▲ +19.08%$23.56 (−1.59%)
Jun 3, 2026
17w ago
8-K
MIXED ★ 7/10
$25.06 $27.69▲ +10.49%▲ +11.49%$23.56 (−5.99%)
Showing 10 of 22

US Market Status

Market Open — Closes in 3h 44m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access
Report published Apr 16, 2026